Navigation Links
Neuralstem Reports First Quarter Financial Results and Provides Business and Clinical Update
Date:5/10/2011

ROCKVILLE, Md., May 10, 2011 /PRNewswire/ --Neuralstem, Inc. (NYSEAmex: CUR)  reported its financial results for the three months period ended March 31, 2011 and provided a business and clinical update.  

(Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO)

"The Company reached several major milestones in the first Quarter of 2011.  Interim data from our Phase I trial for ALS was presented at the American Academy of Neurology Annual Meeting in April, where the principal investigator of the trial, Dr. Eva Feldman, reported the ground-breaking work was both feasible and safe," said Neuralstem's Chairman and Chief Scientific Officer Karl Johe, PhD. "We completed all of the transplantations for the first 12-patient cohort in our ALS trial in mid-April. Also, in February, the U.S. FDA Office of Orphan Products Development granted the Company orphan drug designation for the cell therapy treatment of ALS with its human spinal cord-derived neural stem cells (NSI-566RSC)."

"Further, after receiving approval from the FDA late in 2010 for our first small molecule drug  trial, NSI-189 for major depression, we began dosing in our phase 1a patients in February," said Dr. Johe. "Looking forward, we expect the FDA to approve the second part of the Phase I ALS trial this summer. The next group of patients will receive injections in the upper spinal cord area, where we believe that the injections can ultimately aid in the preservation of respiratory capacity for ALS patients. Additionally, we expect the NSI-189 major depression trial to proceed to Phase Ib with escalating dosing of depressed patients this summer.  The small molecule program has been strengthened by the addition of Maurizio Fava, MD, Director of the Massachusetts General Hospital Department of Psychiatry Clinical Trials Network and Institute, who is now consulting on the trial des
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Former Capital One Director and Business Leader Stanley I. Westreich Joins Neuralstems Board
2. Neuralstem, Inc. Settles Litigation Against ReNeuron, Ltd.
3. Neuralstem, Inc. to Present At World Stem Cells and Regenerative Medicine Congress
4. Neuralstem Completes $5.25 Million Financing
5. Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update
6. Neuralstem Receives FDA Approval to Commence First ALS Stem Cell Trial
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Neuralstem, Inc.
8. Neuralstem to Present at the 11th Annual BIO CEO & Investor Conference
9. Neuralstem Receives Final Notice of Allowance for New Stem Cell Immortalization Technology Patent
10. Neuralstem CEO to Speak on ALS Panel at World Stem Cell Summit
11. Neuralstem Reports Second Quarter Financial Results and Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... N.J. , July 22, 2014 The Board ... BDX ) has declared a quarterly dividend of 54.5 ... holders of record on September 9, 2014. The indicated annual ... About BD BD is a leading medical technology company ... the world,s most pressing and evolving health needs. Our innovative ...
(Date:7/22/2014)... Baughn, a senior lecturer in mechanical engineering at the ... of the Year by the North Texas section of ... has more than 130,000 members in 158 countries who ... to assist the engineering community, benefiting the world. , ... Society of Professional Engineers honors banquet. Baughn retired as ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 Automated cell ... and maintenance of cell culture. They allow production of ... needs of researchers in drug discovery and industries and ... in mAb production, iPSC research, cryobanking, cell-based assays, and ... contamination risk. , Analysts forecast the Global Cell ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 OHAUS ... portable, and mechanical balances and scales, proudly announces ... has won Laboratory Equipment magazine’s 2014 “Readers' Choice” ... second consecutive year the Explorer was voted the ... annual Readers’ Choice Awards celebrates “excellence in product ...
Breaking Biology Technology:UT Dallas professor receives Engineer of the Year award 2Global Cell Culture Market to Grow at 10.27% CAGR by 2018 Forecasts a New Research Report ReportsnReports.com 2Global Cell Culture Market to Grow at 10.27% CAGR by 2018 Forecasts a New Research Report ReportsnReports.com 3Global Cell Culture Market to Grow at 10.27% CAGR by 2018 Forecasts a New Research Report ReportsnReports.com 4OHAUS Explorer Voted “Best Balance” in Laboratory Equipment’s 2014 Readers’ Choice Awards 2
... to Reveal Successful Strategies for China, India at the PharmAsia... -- SAN FRANCISCO, October 13, 2010 ... ... (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so we need ...
... Calif., Oct. 13 Biomerix Corporation ... Patent and Trademark Office (USPTO) has granted ... technology titled "Reticulated elastomeric matrices, their manufacture ... platform technology, the Biomerix Biomaterial™ is a ...
... RICHLAND, Washington A redesign of sodium-nickel chloride batteries ... with rechargeable batteries. Replacing their typical cylindrical shape with ... 30 percent more power at lower temperatures, according to ... October 8 issue of ECS Transactions , a ...
Cached Biology Technology:Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia Summit in San Francisco 2Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia Summit in San Francisco 3Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia Summit in San Francisco 4Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia Summit in San Francisco 5Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia Summit in San Francisco 6Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia Summit in San Francisco 7Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia Summit in San Francisco 8Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia Summit in San Francisco 9Biomerix Granted US Patent for Its Proprietary Biomaterial Platform Technology 2Planar power 2
(Date:7/23/2014)... emulsions are crucial for providing essential fatty acids ... intravenous feeding. There has been concern that soybean-based ... damage due to its composition. Combination lipid emulsions ... oil have been developed to address this concern. ... found that concern may be unwarranted, according to ...
(Date:7/22/2014)... Aware, Inc. (NASDAQ: AWRE ), a ... results for its second quarter ended June 30, 2014. ... million, an increase of 53% compared to $4.4 million in ... income in the second quarter of 2014 was $1.4 million ... The increase in revenue and operating income was driven by ...
(Date:7/22/2014)... scientific discovery showed that mutations in prickle genes ... disorder characterized by repeated seizures over time. However, ... unknown. , A new University of Iowa study, ... of the National Academy of Sciences , reveals ... UI researchers have identified the basic cellular mechanism ...
Breaking Biology News(10 mins):Aware, Inc. Reports Second Quarter 2014 Financial Results 2Aware, Inc. Reports Second Quarter 2014 Financial Results 3Aware, Inc. Reports Second Quarter 2014 Financial Results 4Aware, Inc. Reports Second Quarter 2014 Financial Results 5Aware, Inc. Reports Second Quarter 2014 Financial Results 6Aware, Inc. Reports Second Quarter 2014 Financial Results 7UI study finds potential genetic link between epilepsy and neurodegenerative disorders 2
... This release is available in German . ... the numerous biological functions of an organism are not regulated ... mechanisms exist that contribute to determining the fate of genes. ... even be passed on to subsequent generations to a certain ...
... University engineers have taken a first step toward a ... with heat administered from the end of a catheter. ... technically possible to treat brain tumors without the side ... chemotherapy or radiation. The bioengineers designed and built ...
... N.C. In 2004, researchers at the University of ... announced a crucial discovery in the understanding of cellular ... age, the expression of a key protein, called p16INK4a, ... is a tumor suppressor protein, cancer researchers are interested ...
Cached Biology News:New piece found in the puzzle of epigenetics 2Potential for non-invasive brain tumor treatment 2Test detects molecular marker of aging in humans 2
... Signet offers the most comprehensive, ... requirements. We have incorporated unprecedented quality ... capabilities. This includes proven detection chemistries ... to the TechMate protocol. It also ...
... Each Signet Level 2 Detection System ... avidin-biotin chemical bonding principle and Signets ... provide sensitivity, specificity and reliablility. Signet ... in both manual and automated protocols. ...
... Signet Level 2 Detection System combines ... chemical bonding principle and Signets unique ... sensitivity, specificity and reliablility. Signet reagents ... both manual and automated protocols. ...
Each bottle contains: Bromophenol Blue 0.25% w/v , Xylene Cyanol FF 0.25%, Glycerol solution 30% w/v...
Biology Products: